Short answer
Oruka Therapeutics, Inc. (ORKA) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Item 2.02 references Exhibit 99.1, but the provided text contains only exhibit liability and incorporation disclaimers.
Oruka Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 references Exhibit 99.1, but the provided text contains only exhibit liability and incorporation disclaimers
- Investors must review Exhibit 99.1 for Oruka Therapeutics’ fiscal-year 2026 operating and financial results
Item 8.01 · Other Events
- $700.4M gross equity offering from 9,660,000 shares at $72.50 per share
- Offering closed April 30, 2026, providing substantial funding for corporate purposes
- Underwriters hold a 30-day option for 1,449,000 additional shares, creating potential further dilution
- Share issuance increases Oruka’s shares outstanding and may pressure per-share value despite strengthening liquidity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oruka Therapeutics, Inc. 8-K filings
Get the next ORKA 8-K as it lands
Follow ORKA for push alerts, or ask the research agent what this filing means.